Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

ABSTRACT: Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its f...

Descripción completa

Detalles Bibliográficos
Autores principales: Salles, Gilles, Barrett, Martin, Foà, Robin, Maurer, Joerg, O’Brien, Susan, Valente, Nancy, Wenger, Michael, Maloney, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656728/
https://www.ncbi.nlm.nih.gov/pubmed/28983798
http://dx.doi.org/10.1007/s12325-017-0612-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656728/
https://www.ncbi.nlm.nih.gov/pubmed/28983798
http://dx.doi.org/10.1007/s12325-017-0612-x

Ejemplares similares